Exporting Risk? An Investigative Analysis Of Vaccines And Medicines “Not For Use” In The West But Targeted At Africa

By: Silas Mwaudasheni Nande

1. Introduction – Framing the Dilemma

In recent years, observant researchers, health practitioners, and even concerned citizens across Africa have noticed a curious and troubling trend. Pharmaceutical products, especially vaccines and experimental treatments, often carry labels stating: “Not for use in the USA, Canada, or EU countries.” Even more alarming, some are labeled specifically as “For use in Africa” or “For use in developing countries only.” This seemingly simple disclaimer raises critical questions: Why are these products, developed in Western laboratories and backed by global pharmaceutical giants, deemed unfit or restricted for use in the countries that produce them? Why are these same products then exported and deployed in mass public health campaigns across the Global South – particularly in Africa?

This discrepancy is not just a matter of regulatory differences or international health policy. It strikes at the heart of global pharmaceutical ethics, colonial legacies in medicine, and Africa’s vulnerable dependence on external health solutions. In a continent where local production of medicine is almost nonexistent, and where millions depend on imported drugs for survival, Africa is at a crossroads. Are African lives being treated as experimental commodities? Or is this a misunderstood but necessary mechanism in a global system of health innovation and disease control?

The COVID-19 pandemic further exposed this discrepancy. Some vaccines administered widely in Africa had not received full regulatory approval in the West, and in some cases, were rejected altogether. Yet they were distributed by international organizations in massive public health campaigns. Similar concerns surround malaria, cholera, HPV, and tuberculosis vaccines.

In this investigative article, there is a deep dive into the production and distribution of Western-developed medicines and vaccines that are barred for domestic use yet actively exported. The article scrutinizes the roles of pharmaceutical companies, international health agencies, and regulatory bodies. It also examines the historical context of medical experimentation in Africa, the continent’s fragile pharmaceutical infrastructure, and what this means for sovereignty, safety, and self-reliance in African health systems. From the ethics of emergency authorizations to the economic interests of Big Pharma, this article provides a fact-based, critical, and nuanced discussion.

The article asks the uncomfortable but necessary question: Is Africa safe in the hands of pharmaceutical giants whose products they themselves would not consume?

2. Understanding the Label: “Not for Use in the USA/EU”

Labels indicating that a medicine or vaccine is “Not for Use” in developed countries typically mean the product has not been approved by that country’s regulatory agency. For example, the FDA, EMA, and Health Canada follow stringent requirements in terms of safety, efficacy, and long-term testing before approving any drug. If a pharmaceutical product fails to meet these standards, it cannot be legally sold or administered within those jurisdictions. However, those same products are often rebranded and exported to developing countries where oversight is weaker.

Such labels also act as legal shields for pharmaceutical companies. In the event of adverse reactions or deaths in Western countries, companies are liable for lawsuits and massive financial penalties. These risks are reduced when exporting to Africa, where legal redress systems are often weak or nonexistent. For pharmaceutical giants, Africa represents a lucrative, underregulated market, protected by global aid funding, humanitarian language, and legal impunity.

The reality is that these disclaimers are not mere regulatory notes but powerful ethical signposts. They indicate the existence of a dual standard in global healthcare where African lives are, intentionally or otherwise, subject to lower protection and less scrutiny.

3. The Regulatory Loopholes and Fast-Tracking in Developing Countries

One reason pharmaceutical companies can export unapproved drugs to Africa is the existence of emergency use authorizations and special pathways created by the World Health Organization (WHO) and national governments. WHO’s prequalification program, meant to streamline access to essential medicines in low-income countries, is often used by countries lacking strong drug regulation systems. While the intent is noble, it also opens the door to less tested or experimental medicines.

In Africa, most countries do not have their own Food and Drug Authority equivalent, or if they do, these institutions are poorly funded and highly dependent on foreign data and WHO endorsements. As a result, drugs that have not passed full Phase III trials or that use older and riskier adjuvants may still be approved quickly if the perceived benefits outweigh risks in a public health emergency. This fast-tracking process is easily manipulated, especially by powerful donors, NGOs, and multinational pharmaceutical companies.

4. Historical Context: Medical Experimentation in Africa

Africa’s relationship with Western medicine has been shaped by a long and painful history of exploitation. During the colonial era, African subjects were routinely used in vaccine and drug trials without consent. From syphilis experiments in the Belgian Congo to forced sterilizations and contraceptive trials in South Africa, the continent has seen egregious medical abuses.

This historical memory persists. In 1996, Pfizer conducted an unauthorized clinical trial of an experimental meningitis drug, Trovan, in Nigeria. The trial led to the deaths of several children and permanent injuries in others. The resulting legal battle highlighted the continued vulnerability of African populations to unethical pharmaceutical practices. Today, the shadow of these past abuses looms large over contemporary concerns about double standards in vaccine distribution.

5. Case Studies of Controversial Vaccines and Medicines Sent to Africa

Several specific cases underscore the pattern of exporting questionable or under-tested drugs to Africa:

1. Trovan (Pfizer, 1996): An Experiment Amid Crisis

In 1996, during a deadly meningitis outbreak in Kano, northern Nigeria, Pfizer conducted a clinical trial of an experimental antibiotic called Trovan (trovafloxacin) on nearly 200 children. At the time, Trovan had not been approved for pediatric use in the United States due to serious safety concerns, including risks of liver damage and death. Without fully informed consent from the children’s parents and with inadequate ethical oversight, Pfizer administered the drug alongside a control group that received a reduced dose of ceftriaxone, a standard treatment.

The trial resulted in the deaths of 11 children, while others suffered long-term disabilities such as brain damage, paralysis, or loss of sight and hearing. Allegations emerged that the documentation used to justify the trial had been backdated and that ethical approval had never been properly obtained. After years of legal battles, including a 2001 lawsuit by the Nigerian government and individual families, Pfizer eventually settled the case in 2009 by agreeing to pay $75 million. However, the incident left a deep scar, symbolizing how multinational pharmaceutical companies have at times exploited African emergencies to bypass regulatory standards that would be unthinkable in Western countries.

This case exposed not only the vulnerabilities in African health systems but also the asymmetry in ethical standards applied globally. It remains a cautionary tale about the consequences of conducting clinical research in crisis zones without transparency, informed consent, or robust oversight.

2. HPV Vaccines: Africa as a Regulatory Exception

Human Papillomavirus (HPV) vaccines, such as Cervarix and Gardasil, have been heralded for their potential to prevent cervical cancer. However, in several African countries, particularly in Eastern and Southern Africa, versions of these vaccines were administered with adjuvants (immune-response boosters) that had either not been widely used or were not approved for the same demographic populations in Europe or North America.

These formulations included AS04, an adjuvant based on monophosphoryl lipid A, which had raised concerns in some scientific circles about potential links to autoimmune disorders and chronic fatigue-like syndromes. In parts of Africa, the vaccines were distributed in mass campaigns funded and promoted by international organizations like GAVI and WHO, often with limited post-vaccination monitoring, especially in rural areas. Critics argue that proper informed consent, community education, and long-term follow-up on side effects were inadequate or absent, leaving many questions about the potential long-term impacts of these vaccination campaigns.

Moreover, the socio-economic context—low health literacy, limited media freedom, and high trust in foreign aid—meant that adverse events were rarely reported or investigated thoroughly. While HPV vaccines have undeniable public health value, their rollout in Africa, with formulations and oversight that would not be permitted elsewhere, raises legitimate concerns about double standards in global health ethics.

3. COVID-19 Vaccines: A Two-Tiered Vaccine World

During the COVID-19 pandemic, many African countries received vaccines through the COVAX initiative, a global partnership led by Gavi, CEPI, and the WHO to promote equitable vaccine access. While well-intentioned, the program also exposed the hierarchy in vaccine quality. Several vaccine brands delivered to African nations—including Covaxin (India), Sinopharm (China), and Sputnik V (Russia)—never received full approval from the U.S. FDA or the European Medicines Agency (EMA), and were rejected or avoided by wealthier nations.

In some cases, such as with AstraZeneca, doses were sent to African countries after being pulled from circulation in Western countries due to concerns about blood clotting. Others, like Sinopharm and Sinovac, were approved under emergency use listings, but faced doubts over transparency in clinical trial data and long-term efficacy. Moreover, infrastructure challenges meant that cold chain requirements were not always met, and follow-up for adverse events was minimal.

This created a de facto two-tier vaccine system: high-income nations received mRNA-based vaccines with extensive testing and regulatory oversight, while African countries were expected to accept what was available, often without the same scrutiny. Though millions were vaccinated and some protection achieved, the uneven standards and limited choice raise profound ethical questions about global solidarity, vaccine diplomacy, and medical autonomy.

4. Antimalarial Drugs: A Market Flooded with Substandard Medications

Malaria remains one of Africa’s deadliest diseases, killing hundreds of thousands annually, especially children under five. To combat it, international donors have pumped billions of dollars into supplying antimalarial drugs, primarily through initiatives such as the Global Fund, USAID, and UNICEF. However, numerous investigations have revealed that many of these donated drugs—especially artemisinin-based combination therapies (ACTs)—are substandard or counterfeit.

The WHO has acknowledged that over 15% of antimalarial drugs in sub-Saharan Africa may be substandard or falsified, with some estimates placing the number even higher. These drugs often contain less than the required dose, improper ingredients, or none of the active ingredient at all. Poor procurement practices, lack of stringent regulatory oversight, and decentralized donor distribution channels have allowed these medicines to enter the public supply chain—undermining treatment effectiveness, increasing resistance, and costing lives.

Moreover, many local drug regulatory authorities are underfunded and politically weak, unable to enforce rigorous testing or reject questionable consignments. In some cases, African countries have accepted bulk shipments of antimalarials with expired shelf lives or without sufficient quality certification, simply because rejecting them would mean leaving populations without any treatment. This dangerous trade-off highlights how Africa’s dependency on donor-funded medicine leaves it vulnerable not only to poor-quality drugs but also to long-term health crises driven by drug resistance.

These case studies demonstrate that Africa often receives pharmaceutical products that would not meet the minimum regulatory or ethical standards elsewhere.

6. The Role of Global Health Institutions: WHO, GAVI, Gates Foundation

Global health institutions often act as intermediaries between pharmaceutical companies and African governments. WHO, GAVI, the Global Fund, and the Gates Foundation play significant roles in funding, procuring, and recommending medicines and vaccines. While their contributions to disease reduction are undeniable, their influence also creates a power imbalance. These organizations often bypass local oversight structures in the name of efficiency or urgency.

Moreover, they are not neutral players. The Gates Foundation, for instance, invests in pharmaceutical companies and simultaneously funds global vaccine campaigns, raising questions about conflicts of interest. WHO’s dependence on voluntary funding from the same donors it is supposed to regulate weakens its impartiality. This convergence of interests often leaves African countries unable to push back against questionable medical interventions.

7. Economic and Political Incentives for Western Countries

Western nations have both economic and political incentives to export unapproved or surplus drugs to Africa. Pharmaceutical companies avoid the cost of destroying expired or unsold products. They also secure tax incentives and favorable public relations by donating or selling these products at discounted rates through humanitarian channels.

Politically, vaccine diplomacy helps strengthen alliances and influence policy in recipient countries. During the COVID-19 pandemic, countries like China and Russia also used vaccine donations to expand their geopolitical reach in Africa. Western countries were quick to follow suit, often offloading vaccines nearing expiry.

8. Africa’s Pharmaceutical Landscape: Dependence and Underdevelopment

Africa imports over 70% of its pharmaceuticals. Most countries lack the infrastructure, capital, or regulatory systems to manufacture essential medicines locally. This dependence on external sources makes African nations vulnerable to medical dumping, price manipulation, and supply chain shocks.

Local pharmaceutical industries are underdeveloped due to years of policy neglect, lack of investment, intellectual property restrictions, and poor access to research data. Until this situation changes, Africa will remain dependent on whatever drugs the global North decides to supply – approved or not.

9. Ethical Concerns and the Debate on Medical Apartheid

Critics have called the unequal distribution of medicines and vaccines a form of ‘medical apartheid,’ where the lives of people in poor nations are treated as less valuable. The notion that unapproved or lower-quality drugs are acceptable for Africans but not for Westerners reflects a colonial mindset masked by humanitarian rhetoric.

Ethicists argue that all human beings, regardless of geography, race or skin color, deserve equal standards of medical care and protection. Anything less constitutes a violation of human rights. Africa’s health sovereignty is undermined when it becomes a passive recipient of medical products not considered safe or good enough for others.

10. Interviews and Opinions from African Medical Experts

One Namibian doctor (name withheld for ethical reasons), warns: “We are always told these drugs are safe. But when we ask for raw data or phase trial results, they are not available. That is unacceptable.”

A South African pharmacologist based in Namibia (name withheld), notes: “The lack of transparency and informed consent in vaccine campaigns funded by foreign donors is deeply worrying. Our governments must reclaim regulatory power.”

These voices echo a growing chorus of African professionals demanding stronger local institutions, independent oversight, and transparent partnerships.

11. Is Africa Safe? A Critical Risk Assessment

Given current trends, Africa is not safe. Its dependence on external pharmaceutical products without independent verification exposes its populations to unknown risks. The lack of robust pharmacovigilance means that adverse effects often go unreported or uninvestigated.

Moreover, the absence of legal and ethical accountability creates a permissive environment for pharmaceutical overreach. Until Africa develops its own regulatory frameworks, manufacturing plants, and research capacity, it will remain vulnerable to being used as a testing ground.

12. What Can Be Done? Solutions and Paths to Pharmaceutical Sovereignty

Africa must invest in domestic pharmaceutical manufacturing. Regional hubs, such as in South Africa, Nigeria, Ethiopia and or Egypt, should be supported to produce vaccines and medicines locally. Governments must also develop or strengthen independent regulatory agencies.

Educational institutions need to train the next generation of pharmacists, researchers, and bioethicists. Additionally, Africa must demand greater transparency and insist on equal standards when receiving foreign aid or drug donations.

13. Conclusion: Towards Ethical Equity and Future of Medical Sovereignty

 in Global Health

Africa deserves more than to be treated as a passive recipient in the global health chain. It deserves transparency, respect, and equity – not just in rhetoric, but in policy, production, and partnership. The labeling of certain medicines and vaccines as “not for use in the USA, Canada, or EU” while simultaneously directing them to African populations is not just a regulatory footnote; it is a symptom of a global double standard that undermines African dignity, health, and autonomy.

This is not merely a matter of policy – it is a moral crisis. When life-saving drugs and vaccines are deemed unsuitable for Western populations but are nonetheless shipped to African nations – often with little scrutiny or public awareness – it sends a clear, if unspoken, message: African lives are less valued. Whether cloaked in the language of humanitarian aid, development assistance, or emergency response, these practices erode public trust and deepen the divide between the global North and South.

Africa’s future health security cannot be outsourced. It must be built on a foundation of scientific self-determination, regulatory independence, and ethical accountability. A continent with 1.4 billion people, immense intellectual capital, and rising political consciousness cannot afford to remain at the mercy of foreign pharmaceutical interests or geopolitical donors whose motivations may not always align with public health.

True health sovereignty means developing robust local pharmaceutical industries, strengthening regulatory bodies like the Africa Medicines Agency (AMA), and investing in homegrown research and development. It means demanding full disclosure of clinical trials, ingredients, and safety standards – not as a favor, but as a right. It means ending dependency and moving toward a future where Africa can make and control its own medical destiny.

The era of double standards – however veiled in humanitarianism – must end. The global health community must recognize Africa not as a testing ground or a secondary market, but as an equal stakeholder. Only then can we begin to repair the legacy of exploitative medicine and build a future where no child, no mother, no elder is ever treated as expendable.

The time for reform is not tomorrow. It is now!